(MedPage Today) — Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful reductions in body weight among adults with obesity, a phase II randomized trial showed.
The mean percent…
Source link : https://www.medpagetoday.com/meetingcoverage/obesityweek/118370
Author :
Publish date : 2025-11-07 16:51:00
Copyright for syndicated content belongs to the linked Source.
